Proteon Therapeutics (PRTO) Reports Q2 Loss of $0.31/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Proteon Therapeutics (PRTO) Phase 1 Study of Vonapanitase in PAD Shows Drug Well-Tolerated
August 13, 2015 4:48 PM EDTProteon Therapeutics Inc. (Nasdaq: PRTO) today announced top-line results from its Phase 1 study of investigational vonapanitase in patients with symptomatic peripheral artery disease (PAD). This study evaluated the safety and technical feasibility of a single treatment of vonapanitase via a drug-delivery catheter on atherosclerotic human arteries. The data indicate that catheter-based treatment with vonapanitase was generally well tolerated and technically feasible.
The open-label, single center Phase 1 dose escalation study enrolled 14 patients being treated with balloon angioplasty due to symptomatic PAD of the superficial... More
Proteon Therapeutics (PRTO) Issues Encouraging Update on Vonapanitase Phase 1 Top-Line Data
August 13, 2015 4:46 PM EDTProteon Therapeutics (NASDAQ: PRTO) announced top-line results from its Phase 1 study of investigational vonapanitase in patients with symptomatic peripheral artery disease (PAD). This study evaluated the safety and technical feasibility of a single treatment of vonapanitase via a drug-delivery catheter on atherosclerotic human arteries. The data indicate that catheter-based treatment with vonapanitase was generally well tolerated and technically feasible.
The open-label, single center Phase 1 dose escalation study enrolled 14 patients being treated with balloon angioplasty due to symptomatic PAD of the superficial femoral or... More
